Diabetic retinopathy as a cause of visual impairment and blindness and the possibilities of prevention by using anti vascular endothelial growth factors.: A literature review
Independent thesis Advanced level (degree of Master (Two Years)), 10 credits / 15 HE creditsStudent thesis
Purpose of literature review
Diabetic retinopathy is a very important public health problem and an important cause of visual impairment and blindness worldwide. In addition, visual impairment and blindness are very important public health problems. The number of diabetic retinopathy patients is expected to increase all over the world in the next few decades. In addition, diabetic retinopathy and its complications are still the leading causes of preventable blindness in working-age men and women. Anti-VEGFs have made a revolution in the prevention of visual impairment and blindness caused by diabetic retinopathy and its complications over the last ten years.
The aim of this literature review is to provide an overview of studies and articles which examined the role of Anti-VEGFs (Avastin and Lucentis) in the prevention of visual impairment and blindness caused by diabetic retinopathy.
Pubmed database was searched for relevant articles, studies and clinical trials in humans about the role of anti vascular endothelial growth factors in the prevention of visual impairment and blindness caused by diabetic retinopathy.
Results and discussion
In this review, sixteen studies and articles about the role of Anti-VEGFs in the prevention of visual impairment and blindness caused by diabetic retinopathy were found. These studies and articles emphasized on the role of intravitreal Anti-VEGFs in the treatment of diabetic retinopathy and diabetic macular edema and in the prevention of visual impairment and blindness in proliferative diabetic retinopathy and diabetic macular edema. Intravitreal Anti-VEGFs have shown good effects and promising results in their ability to make retinal neovascularization regress. But these Anti-VEGFs have an important limitation which is their short duration. In addition, these Anti-VEGFs cannot substitute the laser treatment which is the treatment of choice for proliferative diabetic retinopathy.
The introduction of Anti-VEGFs into practice gave hope to many diabetic retinopathy patients facing the threat of visual impairment and blindness. However, using intravitreal Anti-VEGFs is a valuable additional treatment in proliferative diabetic retinopathy and diabetic macular edema to prevent visual impairment and reduce the chances of blindness.
Place, publisher, year, edition, pages
2016. , 39 p.
Centre for Public Health Report Series, ISSN 1651-341x ; 2016:30
Diabetic retinopathy, proliferative diabetic retinopathy, Anti-VEGF, anti vascular endothelial growth factor, Avastin, Lucentis, blindness, prevention of blindness.
Public Health, Global Health, Social Medicine and Epidemiology
IdentifiersURN: urn:nbn:se:umu:diva-131626OAI: oai:DiVA.org:umu-131626DiVA: diva2:1075225
Master's Programme in Public Health
2016-05-23, Umeå Universitet, Umeå, 14:34 (English)
Byass, Peter, Professor
San Sebastian, Miguel, Professor